# EDGAR Filing Document

**Accession Number:** 0001815903
**File Stem:** 0001104659-26-060359
**Filing Date:** 2026-5
**Character Count:** 129221
**Document Hash:** 93fd09cff1d122bdd692df449f0df884
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-060359.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001104659-26-060359

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 54

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Petros Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001815903
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851410058
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39752
- **FILM NUMBER:** 26974427

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 973-242-0005

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

?xml version='1.0' encoding='ASCII'? Petros Pharmaceuticals, Inc._March 31, 2026

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 10-Q**

**(Mark One)**

☒&nbsp;&nbsp;&nbsp;&nbsp;**Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**for the quarterly period ended March 31, 2026**

**Or**

☐&nbsp;&nbsp;&nbsp;&nbsp;**Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**for the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**Commission File Number: 001-39752**

## Petros Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **85-1410058** |
| (State of Incorporation) | (I. R. S. Employer Identification No.) |
| **1185 Avenue of the Americas, 3rd Floor, New York, New York** | **10036** |
| (Address of principal executive offices) | (Zip Code) |

---

**(973) 242-0005**

(Registrant's telephone number, including area code)

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒

As of May 12, 2026, there were 42,372,260 shares of the registrant's common stock, par value $0.0001 per share, outstanding.

------

[**Table of Contents**](#TOC)

#### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q may contain or incorporate by reference forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such forward-looking statements are based upon management's assumptions, expectations, projections, intentions and beliefs about future events. Except for historical information, the use of predictive, future-tense or forward-looking words such as "intend," "plan," "predict," "may," "will," "project," "target," "strategy," "estimate," "anticipate," "believe," "expect," "continue," "potential," "forecast," "should" and similar expressions, whether in the negative or affirmative, that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. Such forward-looking statements are only predictions, and actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of risks and uncertainties, including, without limitation, Petros' ability to execute on its business strategy, including its plans to develop and commercialize a proprietary Rx-to-OTC switch technology; Petros' ability to comply with obligations as a public reporting company; the ability of Petros to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002; risks resulting from Petros' status as an emerging growth company, including that reduced disclosure requirements may make shares of Petros' common stock, par value $0.0001 per share ("Common Stock"), less attractive to investors; risks related to Petros' ability to continue as a going concern; risks related to Petros' history of incurring significant losses; risks related to Petros' ability to obtain regulatory approvals for, or market acceptance of, its Rx-to-OTC switch technology. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are described in this Quarterly Report on Form 10-Q, in "Risk Factor Summary" and in Part I, Item 1A., "Risk Factors," in Petros' [Annual Report on Form 10-K for the year ended December 31, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1815903/000110465926043822/tmb-20251231x10k.htm), and in our other reports filed with the Securities and Exchange Commission (the "SEC"). We advise you to carefully review the reports and documents we file from time to time with the SEC, particularly our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and our current reports on Form 8-K. Petros cautions readers that the forward-looking statements included in, or incorporated by reference into, this Quarterly Report on Form 10-Q represent our beliefs, expectations, estimates and assumptions only as of the date hereof and are not intended to give any assurance as to future results. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, Petros cannot assess the effect of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement.

Readers are cautioned not to place undue reliance on forward-looking statements because of the risks and uncertainties related to them and to the risk factors. We disclaim any obligation to update the forward-looking statements contained in, or incorporated by reference into, this Quarterly Report on Form 10-Q to reflect any new information or future events or circumstances or otherwise, except as required by the federal securities laws.

#### OTHER INFORMATION
All references to "Petros," the "Company," "we," "us" and "our" in this Quarterly Report on Form 10-Q refer to Petros Pharmaceuticals, Inc. and its subsidiaries.

[**Table of Contents**](#TOC)

#### **TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | Page |
| [PART I—FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_522375) | 4 |
| [Item 1. Unaudited Financial Statements](#ITEM1FINANCIALSTATEMENTS_747703) | 4 |
| [Unaudited Condensed Consolidated Balance Sheets as of March 31, 2026, and December 31, 2025](#CONSOLIDATEDBALANCESHEETS_282994) | 4 |
| [Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2026, and 2025](#CONSOLIDATEDSTATEMENTSOFOPERATIONS_22262) | 5 |
| [Unaudited Condensed Consolidated Statements of Changes in Temporary Equity and Stockholders' Equity for the three months ended March 31, 2026, and 2025](#CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHO) | 6 |
| [Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026, and 2025](#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_347107) | 7 |
| [Notes to Unaudited Condensed Consolidated Financial Statements](#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_7) | 8 |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.](#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF) | 18 |
| [Item 3. Quantitative and Qualitative Disclosures About Market Risk.](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR) | 27 |
| [Item 4. Controls and Procedures.](#ITEM4CONTROLSANDPROCEDURES_268415) | 27 |
| [PART II—OTHER INFORMATION](#PARTIIOTHERINFORMATION_691240) | 28 |
| [Item 1. Legal Proceedings.](#ITEM1LEGALPROCEEDINGS_287145) | 28 |
| [Item 1A. Risk Factors.](#ITEM1ARISKFACTORS_428491) | 28 |
| [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.](#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES) | 28 |
| [Item 3. Defaults Upon Senior Securities.](#ITEM3DEFAULTSUPONSENIORSECURITIES_668607) | 28 |
| [Item 4. Mine Safety Disclosures.](#ITEM4MINESAFETYDISCLOSURES_985597) | 28 |
| [Item 5. Other Information.](#ITEM5OTHERINFORMATION_54435) | 28 |
| [Item 6. Exhibits.](#ITEM6EXHIBITS_398792) | 29 |
| [Signatures.](#SIGNATURES_191725) | 30 |

---

[**Table of Contents**](#TOC)

#### PART I—FINANCIAL INFORMATION

#### ITEM 1. UNAUDITED FINANCIAL STATEMENTS.

#### PETROS PHARMACEUTICALS, INC.

#### CONDENSED CONSOLIDATED BALANCE SHEETS
**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **March 31,** <br>**2026** | **December 31,** <br>**2025** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $4352450 | $5136722 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 42000 | 26876 |
| Total current assets | 4394450 | 5163598 |
| Total assets | $4394450 | $5163598 |
| **Liabilities, Temporary Equity and Stockholders' Equity**  |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | 133304 | 83883 |
| &nbsp;&nbsp;Accrued expenses | 190634 | 142486 |
| &nbsp;&nbsp;Accrued Series A convertible redeemable preferred payments payable | 2298297 | 2065475 |
| &nbsp;&nbsp;Warrant liability | 900 | 900 |
| Total current liabilities | 2623135 | 2292744 |
| Total liabilities | $2623135 | $2292744 |
| Commitments and contingencies |  |  |
| Series A convertible redeemable preferred stock (par value $0.0001 per share and $1,000 stated value), 15,000 and 15,000 shares authorized at March 31, 2026, and December 31, 2025, respectively; 0 and 0 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively |  |  |
| Stockholders' Equity: |  |  |
| Series B convertible redeemable preferred stock (par value $0.0001 per share and $1,000 stated value), 1,000,000 and 1,000,000 shares authorized at March 31, 2026, and December 31, 2025, respectively, 0 and 0 shares issued and outstanding as of March 31, 2026, and December 31, 2025, respectively |  |  |
| Common stock (par value $0.0001 per share, 7,000,000,000 and 250,000,000 shares authorized at March 31, 2026, and December 31, 2025, respectively; 42,372,502 and 42,284,502 issued and outstanding as of March 31, 2026, and December 31, 2025, respectively) | 4237 | 4228 |
| Additional paid-in capital | 114048890 | 114161402 |
| Accumulated deficit | (112281812) | (111294776) |
| Total Stockholders' Equity | 1771315 | 2870854 |
| Total Liabilities, Temporary Equity and Stockholders' Equity | $4394450 | $5163598 |

---

The accompanying Notes are an integral part of the Unaudited Condensed Consolidated Financial Statements.

[**Table of Contents**](#TOC)

#### PETROS PHARMACEUTICALS, INC.

#### CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,**  | **For the Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| Operating expenses: |  |  |
| &nbsp;&nbsp;Selling, general and administrative | $1027179 | $1458349 |
| Total operating expenses | 1027179 | 1458349 |
| Loss from continuing operations | (1027179) | (1458349) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;Warrant issuance costs |  | (10420982) |
| &nbsp;&nbsp;Change in fair value of warrant liability |  | 10632000 |
| &nbsp;&nbsp;Interest income | 40143 | 47790 |
| Total other income, net | 40143 | 258808 |
| Loss before income taxes | (987036) | (1199541) |
| Provision for income taxes |  |  |
| Loss from continuing operations, net of tax | (987036) | (1199541) |
| Loss from discontinued operations |  | (1060481) |
| Net loss | $(987036) | $(2260022) |
| Preferred Stock dividend and cash premiums | (232822) | (275167) |
| Deemed dividend on Series A Preferred warrants |  | (8355824) |
| Net loss from continuing operations attributable to common stockholders | $(1219858) | $(9830532) |
| Net loss from discontinued operations attributable to common stockholders | $— | $(1060481) |
| Basic and Diluted – continuing operations | $(0.03) | $(8.46) |
| Basic and Diluted – discontinued operations | $— | $(0.91) |
| Basic and Diluted | $(0.03) | $(9.37) |
| Weighted average common shares outstanding |  |  |
| Basic and Diluted | 46222502 | 1161791 |

---

The accompanying Notes are an integral part of the Unaudited Condensed Consolidated Financial Statements.

[**Table of Contents**](#TOC)

#### PETROS PHARMACEUTICALS, INC.

#### CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY AND DEFICIT
**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br>**Common**<br>**Stock** | **Common**<br>**Stock**<br>**Amount** | **Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | <br>**Total** |
| **Three Months Ended March 31, 2026** |  |  |  |  |  |
| Balance, December 31, 2025 | 42284502 | $4228 | $114161402 | $(111294776) | $2870854 |
| Stock-based compensation expense | 88000 | 9 | 120310 |  | 120319 |
| Series A Preferred Stock dividends |  |  | (232822) |  | (232822) |
| Net loss |  |  |  | (987036) | (987036) |
| Balance, March 31, 2026 | 42372502 | $4237 | $114048890 | $(112281812) | $1771315 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br>**Common**<br>**Stock** | **Common**<br>**Stock**<br>**Amount** | **Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | <br>**Total** |
| **Three Months Ended March 31, 2025** |  |  |  |  |  |
| Balance, December 31, 2024 | 421124 | $42 | $105740751 | $(113208371) | $(7467578) |
| Stock-based compensation expense |  |  | 80038 |  | 80038 |
| Common Stock and prefunded warrants issued, net of expenses | 1600000 | 160 | (160) |  |  |
| Series A Preferred Stock dividends |  |  | (275167) |  | (275167) |
| Preferred Stock redemption including cash premium | 31638 | 3 | 338518 |  | 338521 |
| Net loss |  |  |  | (2260022) | (2260022) |
| Balance, March 31, 2025 | 2052762 | $205 | $105883980 | $(115468393) | $(9584208) |

---

The accompanying Notes are an integral part of the Unaudited Condensed Consolidated Financial Statements.

[**Table of Contents**](#TOC)

#### PETROS PHARMACEUTICALS, INC.

#### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,**  | **For the Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| **Cash flows from operating activities:** |  |  |
| Net Loss | $(987036) | $(2260022) |
| Less loss from discontinued operations  |  | (1060481) |
| Operating Loss from continuing operations | (987036) | (1199541) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;Change in fair value of warrant liability |  | (10632000) |
| &nbsp;&nbsp;Warrant issuance costs |  | 10420982 |
| &nbsp;&nbsp;Employee stock-based compensation | 120319 | 80038 |
| &nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (15124) | (52520) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 49421 | (211614) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 48148 | 100062 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities – continuing operations | (784272) | (1494593) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities – discontinued operations |  | (165495) |
| &nbsp;&nbsp;Net cash used in operating activities | (784272) | (1660088) |
| **Cash flows from financing activities:** |  |  |
| Proceeds from common stock and prefunded warrants, net |  | 8707002 |
| Net cash provided by financing activities – continuing operations |  | 8707002 |
| Net increase (decrease) in cash  | (784272) | 7046914 |
| &nbsp;&nbsp;Cash and cash equivalents, beginning of period  | 5136722 | 3709971 |
| &nbsp;&nbsp;Cash and cash equivalents, end of period | 4352450 | 10756885 |
| &nbsp;&nbsp;Less: Cash and cash equivalents attributable to discontinued operations  |  | (1825831) |
| &nbsp;&nbsp;Cash and cash equivalents, end of period – continuing operations | $4352450 | $8931054 |
| **Supplemental cash flow information:** |  |  |
| &nbsp;&nbsp;Cash paid for interest during the period | $— | $— |
| **Noncash Items:** |  |  |
| &nbsp;&nbsp;Noncash redemption of Series A Preferred Stock | $— | $338521 |
| &nbsp;&nbsp;Accrual of Series A Preferred Stock dividends | 232822 | 275167 |
| &nbsp;&nbsp;Non-cash warrant issuance costs |  | 18924000 |
| &nbsp;&nbsp;Deemed dividend on Series A Preferred Warrants |  | 8355824 |
| &nbsp;&nbsp;Accrued equity issuance costs |  | 203984 |

---

The accompanying Notes are an integral part of the Unaudited Condensed Consolidated Financial Statements.

[**Table of Contents**](#TOC)

#### PETROS PHARMACEUTICALS, INC.

#### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
**(Unaudited)**

#### 1)&nbsp;&nbsp;&nbsp;&nbsp;Nature of Operations, Basis of Presentation, and Liquidity

#### Nature of Operations and Basis of Presentation
Petros Pharmaceuticals, Inc. ("Petros" or the "Company") was incorporated in Delaware on May 14, 2020, for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (as amended, the "Merger Agreement"), by and between Petros, Neurotrope, Inc., a Nevada corporation ("Neurotrope"), Metuchen Pharmaceuticals LLC, a Delaware limited liability company ("Metuchen"), and certain subsidiaries of Petros and Neurotrope. Prior to June 2025, Petros consisted of wholly owned subsidiaries: Metuchen, Neurotrope, Timm Medical Technologies, Inc. ("Timm Medical"), and Pos-T-Vac, LLC ("PTV" and, collectively with Metuchen and Timm Medical, the "Subsidiaries"). The Company has historically been engaged in the commercialization and development of Stendra®, a U.S. Food and Drug Administration ("FDA") approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction ("ED"), which the Company licensed from Vivus, Inc. ("Vivus"). Petros also historically marketed its own line of ED products in the form of vacuum erection device products ("VEDs") through its previous subsidiaries, Timm Medical and PTV, including VEDs marketed as "Osbon ErecAid" and "PosTVac."

In December 2024, the Company determined to discontinue sales of Stendra® to wholesalers. Beginning in March 2025, the Company is no longer engaged in the commercialization, development or sales of Stendra®. In addition, on June 16, 2025, in accordance with California state law, the Company effected an assignment (the "Assignment") of all of the business, assets, properties, contractual rights, goodwill, going concern value, rights and claims ("Assets") of Metuchen, including Metuchen's wholly-owned subsidiaries, Timm Medical and PTV and each of their respective Assets (collectively, the "ABC Assets"), for the benefit of creditors to a special purpose vehicle that is managed by a third-party fiduciary (the "Assignee") such that, as of June 16, 2025, the Assignee succeeded to all of each Subsidiary's right, title and interest in and to the respective ABC Assets. Upon the completion of the Assignment, the Assignee obtained sole control over the ABC Assets and each Subsidiary no longer operates its business or controls the liquidation or distribution of its assets or the resolution of claims. The Assignment is a judicial insolvency procedure, which was commenced by each Subsidiary entering a contractual assignment for the benefit of creditors on June 16, 2025, that effectuates the assignment, grant, conveyance, transfer, and setting over to the Assignee, in trust, of all of the ABC Assets. Accordingly, the Company is no longer engaged in the marketing or selling of VEDs following the completion of the Assignment. Today, the Company is working towards the goal of becoming a leading innovator in the emerging self-care market driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter ("OTC") and nonprescription drug products with additional condition for nonprescription use ("ACNU Products") treatment options.

Petros is pursuing the development of a proprietary integrated technology solutions platform (the "platform") containing two components (i) SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and (ii) a potential Software as a Medical Device ("SaMD") component, which must comply with FDA governance and approval and is expected to be a consumer interface that guides the consumer in navigating appropriate self-selection or deselection, through the acquisition process of the OTC product. The Company has been working towards the development of the platform, which is currently in early development stages and is being designed to serve as a retail or online interface, with clinically established algorithmic logic qualifying the intended consumer-patient for purchase and use of an ACNU Product, while reducing subjectivity to the least possible degree and maximizing objective qualifiers to the greatest possible degree.

The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and in accordance with the accounting rules under Regulation S-X, as promulgated by the Securities and Exchange Commission ("SEC"). All significant intercompany accounts and transactions have been eliminated in consolidation.

**Reverse Stock Split**

On April 29, 2025, the Company effected a 1-for-25 reverse stock split of its common stock, par value $0.0001 per share (the "Common Stock"), as of April 30, 2025. All share, restricted stock unit ("RSU") and per share or per RSU information has been retroactively adjusted to reflect the reverse stock split.

[**Table of Contents**](#TOC)

#### Liquidity and Going Concern
In accordance with Financial Accounting Standards Board (the "FASB") Accounting Standards Update ("ASU") ASU 2014-15, Presentation of Financial Statements - going Concern (Subtopic 205-40) ("ASC 205-40"), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. To date, the Company's principal sources of capital used to fund the Company's operations have been the revenues from product sales, private sales, registered offerings and private placements of equity securities. The Company has experienced net losses and negative cash flows from operations since the Company's inception. As of March 31, 2026, the Company had cash of $4.4 million, working capital of $1.8 million, and accumulated deficit of $112.3 million. The Company's plans include, or may include, utilizing cash and cash equivalents on hand, as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. The Company does not currently have sufficient available liquidity to fund its operations for at least the next 12 months. These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued.

The accompanying condensed consolidated financial statements do not include any adjustments that might result from these uncertainties. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

In response to these conditions and events, the Company is evaluating various financing strategies to obtain sufficient additional liquidity to meet its operating, debt service and capital requirements for the next twelve months following the date of the Company's condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The potential sources of financing that the Company is evaluating include one or any combination of secured or unsecured debt, convertible debt and equity in both public and private offerings. The Company also plans to finance near-term operations by exploring additional ways to raise capital and increasing cash flows from operations. There is no assurance the Company will manage to raise additional capital or otherwise increase cash flows, if required or that the Company will have sufficient cash to develop its platform, even after the proceeds raised in this offering.

**Metuchen ABC**

On January 18, 2022, Metuchen and Vivus, Inc. ("Vivus") entered into a Settlement Agreement (the "Vivus Settlement Agreement") related to the minimum purchase requirements under the Vivus Supply Agreement in 2018, 2019 and 2020 and certain reimbursement rights asserted by a third-party retailer in connection with quantities of Metuchen's Stendra® product that were delivered to the third-party retailer and later returned. In connection with the Vivus Settlement Agreement, Metuchen retained approximately $7.3 million of API inventory (representing the 2018 and 2019 minimum purchase requirements) out of approximately $12.4 million due under the Vivus Supply Agreement, in conjunction with forgiveness of approximately $4.25 million of current liabilities relating to returned goods and minimum purchase commitments. In exchange for the API and reduction of current liabilities, Metuchen executed an interest-bearing promissory note (the "Note") in favor of Vivus in the principal amount of $10,201,758. The parties also entered into that certain Security Agreement, dated January 18, 2022 ("Security Agreement"), pursuant to which Metuchen granted to Vivus a continuing security interest in all of its Stendra® API and products and its rights under the License Agreement (the "Collateral") to secure Metuchen's obligations under the Note. The Security Agreement contained customary events of default. The Company recorded the impact of this transaction, including the gain in the first quarter of 2022.

In addition to the payments to be made in accordance with the Note, Metuchen further agreed in the Vivus Settlement Agreement to (i) grant to Vivus a right of first refusal to provide certain types of debt and convertible equity (but not preferred equity) financing issued by or to Metuchen (including any subsidiaries and intermediaries) until the Note is paid in full, and (ii) undertake to make certain regulatory submissions to effectuate Vivus' ability to exercise its rights under the License Agreement. On January 18, 2022, Metuchen made a prepayment of the obligations under the Note in the amount of $900,000, and a payment of $1,542,904 with respect to a purchase order made in 2021 to Vivus. In consideration of these payments and upon Metuchen's satisfaction of certain regulatory submissions, Vivus released 50% of the quantity of bulk Stendra® tablets under Metuchen's existing open purchase order (the "Open Purchase Order") being held by Vivus, which represented approximately a six-month supply of inventory. Pursuant to the Vivus Settlement Agreement, Vivus released the remaining 50% of the quantity of bulk Stendra® tablets under the Open Purchase Order, later during the first quarter of 2022, upon Metuchen's satisfaction of the remaining regulatory submission requirements.

[**Table of Contents**](#TOC)

On October 1, 2024, Metuchen failed to make the payment due pursuant to the Note and related Security Agreement in the amount of $0.5 million, constituting an Event of Default (as defined in the Note) under the Note and Security Agreement. The outstanding principal amount on the Note, plus accrued and unpaid interest thereon, was $7,574,824 as of December 31, 2024. As a result of an event of default under the Settlement Agreement and the Security Agreement existing and continuing by virtue of Metuchen's failure to pay the Installment (as defined in the Note) that was due October 1, 2024 (the "Vivus Event of Default"), all the obligations under the Settlement Agreement and the Security Agreement (the "Obligations") became immediately due and payable on the date of the Foreclosure Notice (as defined below).

Pursuant to the Security Agreement, Vivus holds a security interest against the Collateral. On December 10, 2024, pursuant to a Notice of Proposal to Accept Pledged Collateral in Partial Satisfaction of Indebtedness Pursuant to Uniform Commercial Code Section 9-620 (the "Foreclosure Notice"), Vivus proposed to accept all the Collateral (save and except the Specified License Agreement (as defined in the Security Agreement); collectively, the "Foreclosed Collateral") in partial satisfaction of the Obligations. Vivus further proposed in the Foreclosure Notice that its acceptance of the Foreclosed Collateral would only constitute satisfaction of $2,000,000 worth of the Obligations and would not include any other amounts outstanding under the Note, the Settlement Agreement, or the Security Agreement, including but not limited to (i) all interest accrued or at any time accruing thereon and (ii) all other sums recoverable by Vivus from Metuchen by virtue of the Obligations. On December 13, 2024, Metuchen accepted and agreed to the Foreclosure Notice.

In connection with the Foreclosure Notice, Metuchen and Vivus entered into that certain termination agreement, dated as of March 31, 2025, pursuant to which, the parties mutually agreed to terminate the Vivus License Agreement, effective as of March 31, 2025 (the "Vivus Termination Agreement"), subject to the survival of certain provisions as set forth therein. As a result of the Vivus Termination Agreement, Metuchen no longer has any right in or to Vivus Technology (as defined in the Vivus License Agreement) in the United States of America and its territories and possessions, including Puerto Rico and U.S. military bases abroad, Canada, South America and India (the "Licensed Territory") and Metuchen agreed to immediately cease the development, manufacturing and commercialization of Stendra® in the Licensed Territory. Metuchen further agreed to assign any trademarks incorporating the mark "Stendra®" to Vivus, subject to certain exceptions as set forth therein. In furtherance of the Foreclosure Notice, and pursuant to the Termination Agreement, Metuchen agreed to transfer all completed inventory of Stendra® and all substantially manufactured inventory of Stendra® on hand to Vivus at Metuchen's sole expense within 30 days of the date of the Vivus Termination Agreement.

Pursuant to the Vivus Termination Agreement, Metuchen agreed to provide transition services to Vivus, including transferring any agreements or arrangements with distributors of Stendra®, to enable the development, manufacturing and commercialization of Stendra® to proceed without disruption. Additionally, Metuchen agreed to transfer to Vivus any regulatory approvals with respect to Stendra® controlled by Metuchen or its affiliates within 30 days of the date of the Vivus Termination Agreement.

Pursuant to the Vivus Termination Agreement, Metuchen further agreed that Metuchen will retain liability for payment of all gross to net sales deductions (including returns, rebates and chargeback) of Stendra® products that were sold prior to the date of the Vivus Termination Agreement and agreed to reimburse Vivus for any such deductions charged to or otherwise borne by Vivus.

On June 16, 2025, in accordance with California state law, the Company effected an assignment (the "Assignment") of all of the business, assets, properties, contractual rights, goodwill, going concern value, rights and claims ("Assets") of Metuchen, including Metuchen's wholly-owned subsidiaries, Timm Medical and PTV and each of their respective Assets (collectively, the "ABC Assets"), for the benefit of creditors to a special purpose vehicle that is managed by a third-party fiduciary (the "Assignee") such that, as of June 16, 2025, the Assignee succeeded to all of each Subsidiary's right, title and interest in and to the respective ABC Assets. Upon the completion of the Assignment, the Assignee obtained sole control over the ABC Assets and each Subsidiary no longer operates its business or controls the liquidation or distribution of its assets or the resolution of claims. The Assignment is a judicial insolvency procedure, which was commenced by each Subsidiary entering a contractual assignment for the benefit of creditors on June 16, 2025, that effectuates the assignment, grant, conveyance, transfer, and setting over to the Assignee, in trust, of all of the ABC Assets. The Assignee is expected to liquidate the property through an auction sale and distribute the proceeds to the Subsidiaries' creditors according to their respective priorities at law to satisfy Metuchen's obligations, including the Obligations, in accordance with the rules and regulations of the State of California. If any proceeds remain after all of Metuchen's obligations, including the Obligations, and costs associated with the liquidation process have been satisfied, any remaining proceeds will be distributed to Metuchen's equity holder, which is the Company (collectively, the "ABC").

[**Table of Contents**](#TOC)

Pursuant to that certain letter agreement (the "Sherwood Agreement"), dated as of March 31, 2025, by and between Metuchen and Sherwood Partners, Inc. ("Sherwood"), Sherwood agreed to provide certain consulting and advisory services in connection with the ABC, including in connection with the sale process and budgeting and planning process (the "Services"). In consideration for the Services, Metuchen has agreed to pay a fee to Sherwood equal to $60,000 and a cash fee equal to 9% of the gross proceeds of the sale of the ABC Assets and has agreed to reimburse Sherwood for certain reasonable out-of-pocket expenses.

#### 2)&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies
**Basis of Presentation and Principles of Consolidation**

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial reporting and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company's financial position and the results of its operations and cash flows for the interim periods presented. Such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2026, may not be indicative of results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes to those statements for the year ended December 31, 2025, included in the Company's Annual Report on Form 10-K filed with the SEC on April 15, 2026. All transactions between the consolidated entities have been eliminated in consolidation.

**Use of Estimates**

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of the valuation of the derivative liability, and the valuation of warrants, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.

#### Discontinued Operations
The results of discontinued operations are reported in income (loss) from discontinued operations, net of taxes in the condensed consolidated statements of operations (loss) for the current and prior periods beginning in the period in which the business meets the held for sale criteria. Income (loss) from discontinued operations includes direct costs attributable to the business held for sale, and an estimate of costs from corporate functions dedicated to the business, but excludes corporate expenses composed of selling, general and administrative expenses not attributable to any of the operating segments (see Note 3).

Unless otherwise indicated, the information in the notes to the condensed consolidated financial statements refers only to the Company's continuing operations.

#### 3)&nbsp;&nbsp;&nbsp;&nbsp;Discontinued Operations
ABC Assets' Discontinued Operations

As a result of the Board ABC Resolution and Sherwood Agreement, as of March 31, 2025, the Company determined that the ABC Assets met the discontinued operations accounting criteria. Accordingly, the Company classified the ABC Assets' operations as discontinued operations in its condensed consolidated statements of operations for all periods presented.

[**Table of Contents**](#TOC)

Condensed Consolidated statement of operations related to the ABC Assets' discontinued operations:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,**  | **For the Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| Net sales | $— | $713539 |
| Cost of goods sold |  | 198903 |
| Gross profit |  | 514636 |
| &nbsp;&nbsp;Selling, general and administrative |  | 1140323 |
| &nbsp;&nbsp;Research and development expense |  | 82186 |
| &nbsp;&nbsp;Depreciation and amortization expense |  | 189514 |
| &nbsp;&nbsp;Interest expense, promissory note |  | 163094 |
| Loss from discontinued operations before income tax |  | (1060481) |
| Provision for income taxes |  |  |
| Loss from discontinued operations | $— | $(1060481) |

---

#### 4)&nbsp;&nbsp;&nbsp;&nbsp;Accrued Expenses
Accrued expenses are comprised of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| Accrued professional fees | $60000 | $142351 |
| Accrued bonuses | 130432 |  |
| Other accrued expenses | 202 | 135 |
| Total accrued expenses | $190634 | $142486 |

---

#### 5)&nbsp;&nbsp;&nbsp;&nbsp;Stockholders' Equity
**Private Placement**

On July 13, 2023, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain accredited investors (the "Investors"), pursuant to which the Company agreed to sell in a private placement to the Investors (i) an aggregate of 15,000 shares of the Company's newly-designated Series A Convertible Preferred Stock, with a par value of $0.0001 per share and stated value of $1,000 per share (the "Series A Preferred Shares"), initially convertible into up to 266,667 shares of the Company's Common Stock, par value $0.0001 per share (the "Common Stock") and (ii) warrants to acquire up to an aggregate of 266,667 shares of Common Stock (the "Warrants") at an initial exercise price of $56.25 per share (collectively, the "Private Placement"). Pursuant to the terms of the Certificate of Designations of Series A Convertible Preferred Stock (the "Certificate of Designations") and the Warrants, each of the Conversion Price (as defined below) and the exercise price and the number of shares underlying the Warrants is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions).

Series A Preferred Stock

The terms of the Series A Preferred Stock are as set forth in the form of Certificate of Designations. The Series A Preferred Stock is convertible into shares of Common Stock (the "Conversion Shares") at the election of the holder at any time at an initial conversion price of $56.25 (the "Conversion Price"). The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions).

Pursuant to the Certificate of Designations and prior to the November 2024 Certificate of Amendment (as defined below) and the January 2025 Certificate of Amendment (as defined below), the Company was initially required to redeem the Series A Preferred Stock in 13 equal monthly installments, which commenced on November 1, 2023.

[**Table of Contents**](#TOC)

On November 13, 2024, the Company entered into an Amendment Agreement with the Required Holders (as defined in the Certificate of Designations), pursuant to which, the Required Holders agreed to (i) amend the Certificate of Designations, by filing a Certificate of Amendment with the Secretary of State of the State of Delaware (the "November 2024 Certificate of Amendment"), (ii) defer any payment amounts that have accrued and that are unpaid as of November 13, 2024, pursuant to the Certificate of Designations, to January 15, 2025, and (iii) waive any breach or violation of the Purchase Agreement, the Certificate of Designations, or the Warrants resulting from the Company's failure to pay such outstanding amounts (the "November 2024 Certificate of Amendment"). The November 2024 Certificate of Amendment amends the Certificate of Designations to, (i) extend the maturity date to January 15, 2025, (ii) modify the schedule of Installment Dates (as defined in the Certificate of Designations), and (iii) adds an additional restrictive covenant to the Certificate of Designations requiring the Company from November 13, 2024 until January 15, 2025, to maintain unencumbered, unrestricted cash and cash equivalents on hand in amount equal to at least $1,500,000. The November 2024 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of November 13, 2024.

On January 23, 2025, the Company entered into an Amendment Agreement with the Required Holders (as defined in the Certificate of Designations (the "Certificate of Designations") of the Company's Series A Convertible Preferred Stock ("Series A Preferred Stock")), pursuant to which, the Required Holders agreed to (i) amend the Certificate of Designations of the Company's Series A Preferred Stock by filing a Certificate of Amendment to the Certificate of Designations (the "January 2025 Certificate of Amendment") with the Secretary of State of the State of Delaware, (ii) defer any payment amounts that have accrued and that are unpaid as of January 23, 2025 pursuant to the Certificate of Designations, to February 15, 2025, and (iii) waive any breach or violation of that certain Purchase Agreement, dated as of July 13, 2023 ("Series A Purchase Agreement"), pursuant to which the Company issued the Series A Preferred Stock and the related warrants (the "Warrants"), the Certificate of Designations, or the Warrants resulting from the Company's failure to pay such outstanding amounts. The January 2025 Certificate of Amendment amended the Certificate of Designations to (i) extend the maturity date to February 15, 2025, (ii) modify the schedule of Installment Dates (as defined in the Certificate of Designations), (iii) amends the restrictive covenant to the Certificate of Designations requiring the Company from January 15, 2025 until February 15, 2025, to maintain unencumbered, unrestricted cash and cash equivalents on hand in amount equal to at least $500,000, and (iv) amends the restrictive covenant relating to the change in nature of the Company's business, such that such covenant does not apply to the Company's change in sales strategy related to the Company's Stendra® avanafil and product development strategy as it relates to the development and commercialization of a proprietary platform focused on prescription medication to over - the - counter switch solutions. The January 2025 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of January 24, 2025.

On March 30, 2025, the Company entered into an Amendment Agreement (the "March 2025 Amendment Agreement") with the Required Holders (as defined in the Certificate of Designations), pursuant to which, the Required Holders agreed to (i) amend the Certificate of Designations of the Company's Series A Preferred Stock by filing a Certificate of Amendment to the Certificate of Designations (the "March 2025 Certificate of Amendment") with the Secretary of State of the State of Delaware, (ii) defer any payment amounts that have accrued and that are unpaid as of the date of the March 2025 Amendment Agreement, pursuant to the Certificate of Designations, to July 15, 2025, and (iii) waive any breach or violation of the Purchase Agreement, the Certificate of Designations, or the Warrants resulting from the Company's failure to pay such outstanding amounts. The March 2025 Certificate of Amendment amends the Certificate of Designations to, (i) extend the maturity date to July 15, 2025, and (ii) modify the schedule of Installment Dates (as defined in the Certificate of Designations). The March 2025 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of March 31, 2025. As of the date of this filing, the liability for accrued Series A Preferred payments payable has not been fully settled and the Certificate of Designations has not been further amended to extend the maturity date as set forth therein.

The amortization payments due upon redemptions are payable, at the Company's election, in cash at 107% of the Installment Redemption Amount (as defined in the Certificate of Designations), or subject to certain limitations, in shares of Common Stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) 80% of the average of the three lowest closing prices of the Common Stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) the lower of $9.90, which is 20% of the "Minimum Price" (as defined in Nasdaq Stock Market Rule 5635) on the date of the Stockholder Approval (as defined in the Purchase Agreement) or such lower amount as permitted, from time to time, by the Nasdaq Stock Market, subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events. The Company may require holders to convert their Series A Preferred Shares into Conversion Shares if the closing price of the Common Stock exceeds $168.75 per share (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) for 20 consecutive trading days and the daily dollar trading volume of the Common Stock exceeds two million dollars ($2,000,000) per day during the same period and certain equity conditions described in the Certificate of Designations are satisfied.

[**Table of Contents**](#TOC)

The holders of the Series A Preferred Shares are entitled to dividends of 8% per annum, compounded monthly, which are payable, at the Company's option, in cash or shares of Common Stock, or in a combination thereof, in accordance with the terms of the Certificate of Designations. On September 29, 2023, the Company filed an amendment to the Certificate of Designations with the Secretary of State for the State of Delaware, pursuant to which the terms of the Series A Preferred Stock were amended to permit certain additional procedures for the payment of redemptions and conversions Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Series A Preferred Shares will accrue dividends at the rate of 15% per annum. In connection with a Triggering Event, each holder of Series A Preferred Shares will be able to require the Company to redeem in cash any or all of the holder's Series A Preferred Shares at a premium set forth in the Certificate of Designations. Upon conversion or redemption, the holders of the Series A Preferred Shares are also entitled to receive a dividend make-whole payment.

The event of default under the Settlement Agreement and the Security Agreement with Vivus existing and continuing by virtue of Metuchen's failure to pay the Installment (as defined in the Promissory Note) that was due October 1, 2024, constituted a Triggering Event pursuant to the terms of the Certificate of Designations. As a result, the dividend rate of the Series A Preferred Stock was automatically increased to 15% per annum beginning on October 1, 2024. On October 11, 2024, the Company entered into an Amendment Agreement with the Required Holders (as defined in the Certificate of Designations) pursuant to which, the Required Holders agreed to amend the Certificate of Designations of the Company's Series A Preferred Stock, by filing a Certificate of Amendment with the Secretary of State of the State of Delaware ("October 2024 Certificate of Amendment"). The October 2024 Certificate of Amendment amends the Certificate of Designations to, among other things, provide that, except as required by applicable law, the holders of the Series A Preferred Stock will be entitled to vote with holders of the Common Stock on an as converted basis, with the number of votes to which each holder of Series A Preferred Stock is entitled to be determined by dividing the Stated Value (as defined in the Certificate of Designations) by a conversion price equal to $56.25 per share, which was the "Minimum Price" (as defined in Nasdaq Listing Rule 5635(d)) applicable immediately before the execution and delivery of the purchase agreement executed in connection with the issuance of the Series A Preferred Stock, subject to certain beneficial ownership limitations and adjustments for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions, as set forth in the Certificate of Designations. The October 2024 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of October 11, 2024.

The Company is subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends (other than dividends pursuant to the Certificate of Designations), distributions or redemptions, and the transfer of assets, among other matters.

There is no established public trading market for the Series A Preferred Shares and the Company does not intend to list the Series A Preferred Shares on any national securities exchange or nationally recognized trading system.

**Series B Preferred Stock**

On February 13, 2025, the Company filed a Certificate of Designations with the Secretary of State of the State of Delaware, establishing the designations, preferences, powers and rights of the shares of a new series of the Company's preferred stock, Series B Convertible Preferred Stock, which was effective immediately on filing (the "Series B Certificate of Designations").

[**Table of Contents**](#TOC)

**February 2025 Equity Financing**

On February 17, 2025, the Company entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional and accredited investors (collectively, the "Investors") for the issuance and sale, in a best efforts public offering (the "Public Offering"), of (i) 558,000 units (the "Units"), each Unit consisting of one share (the "Shares") of the Company's Common Stock, one Series A Warrant (the "Series A Warrants") to purchase 0.25 share of Common Stock (the "Series A Warrant Shares") and one Series B Warrant (the "Series B Warrants," and together with the Series A Warrants, the "Series Warrants") to purchase one share of Common Stock (the "Series B Warrant Shares" and, together with the Series A Warrant Shares, the "Warrant Shares") and (ii) 1,042,000 pre-funded units (the "Pre-Funded Units"), each Pre-Funded Unit consisting of one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock (the "Pre-Funded Warrant Shares"), one Series A Warrant and one Series B Warrant. The public offering price was $6.00 per Unit and $5.9975 per Pre-Funded Unit. The Offering closed on February 19, 2025. The aggregate gross proceeds from the Offering were approximately $9.6 million before deducting estimated offering expenses payable by the Company totaling approximately $1.1 million.

In connection with the Public Offering, (i) the conversion price of the Series A Preferred Stock was adjusted to $6.00 per share pursuant to the full ratchet anti-dilution provisions contained in the Certificate of Designations and, (ii) the exercise price of the Warrants was adjusted to $6.00 per share and the number of shares of Common Stock issuable upon exercise of the Warrants was adjusted proportionally to 2,700,000 shares pursuant to the full ratchet anti-dilution provisions contained in the Warrants (the "Public Offering Warrant Adjustment").

The Company considers the change in exercise price due to the anti-dilution trigger related to the Series A Preferred Warrants to be of an equity nature, as the issuance allowed the warrant holders to exercise warrants in exchange for Common Stock, which represents an equity for equity exchange. Therefore, the change in the fair value of the Warrants before and after the effect of the anti-dilution triggering event will be treated as a deemed dividend in the amount of approximately $8.4 million during the three months ended March 31, 2025. The Company valued the initial deemed dividend as the difference between: (a) the modified fair value of the Warrants in the amount of approximately $9.1 million and (b) the fair value of the original award prior to the modification of approximately $0.7 million. The fair value of the Series A Preferred Warrants before the effect of the anti-dilution triggering event was estimated utilizing the Black Scholes model using the following key inputs and assumptions: the number of shares issuable upon exercise of the Series A Preferred Warrants totaling 288,000; the exercise price of $56.25; dividend yield of 0%; remaining term of 3.40 years; equity volatility of 165.0%; and a risk-free interest rate of 4.3%. The fair value of the Warrants after the effect of the anti-dilution triggering event was estimated utilizing the Black Scholes model and the following key inputs and assumptions: the number of shares issuable upon exercise of the Series A Preferred Warrants totaling 2,700,000; the exercise price of $6.00; dividend yield of 0%; remaining term of 3.40 years; equity volatility of 165.0%; and a risk-free interest rate of 4.3%.

Dawson James Securities, Inc. ("Dawson") acted as the Company's exclusive placement agent in connection with the Public Offering, pursuant to that certain engagement letter, dated as of January 24, 2025, between the Company and Dawson (the "Engagement Letter"). Pursuant to the Engagement Letter, the Company agreed to pay Dawson a cash fee equal to 8.0% of the aggregate gross proceeds of the Public Offering and reimbursed certain expenses and legal fees.

The aggregate gross proceeds from the Public Offering were approximately $9.6 million before deducting estimated offering expenses payable by the Company.

The Company assessed the Pre-Funded Warrants and Series A Warrants under ASC 480 and ASC 815 and determined that the Pre-Funded and Series A Warrants met the requirements to be classified in stockholders' equity. However, the fair value of the Series B Warrants exceeded the proceeds received from the Public Offering, and thus the Pre-Funded Warrants and Series A Warrants were recorded at their residual fair value of $0 upon issuance. Transaction costs incurred attributable to the Series B Warrants of approximately $10.4 million were expensed immediately upon issuance, of which approximately $1.1 million represents cash broker and legal fees, and approximately $9.3 million represents the excess of the $18.9 million issuance date fair value of the Series B Warrants over cash proceeds of $9.6 million (see Note 7).

[**Table of Contents**](#TOC)

**6)&nbsp;&nbsp;&nbsp;&nbsp;Stock-Based Compensation**

The Company held a special meeting of stockholders on April 10, 2025, at which the Company's stockholders approved an amendment to the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan (the "Incentive Plan") to increase the aggregate number of shares of Common Stock available for the grant of awards under the Incentive Plan by 40,000,000, to a total of 40,110,400 shares of Common Stock. As of March 31, 2026, there were 40,110,400 shares authorized and 32,129,087 shares available for issuance under the Incentive Plan.

The following is a summary of restricted stock awards and units for the three months ended March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | <br>**Number of**<br>**Shares** | **Weighted-**<br>**Average**<br>**Grant Date Fair Value** |
| Restricted Stock Awards and Units unvested at December 31, 2025 | 88000 | $6.78 |
| Restricted Stock Awards and Units granted | 7875000 | 0.008 |
| Restricted Stock Awards and Units vested | (3981500) | 0.083 |
| Restricted Stock Awards and Units unvested at March 31, 2026  | 3981500 | $0.083 |

---

Stock-based compensation expense associated with restricted stock awards recognized for the three months ended March 31, 2026, was $120,319 and is recorded in general and administrative expenses in the consolidated statements of operations. As of March 31, 2026, unrecognized stock-based compensation expense is approximately $274,266 to be recognized over a term of 0.86 years.

#### 7)&nbsp;&nbsp;&nbsp;&nbsp;Common Stock Warrants
The following is a summary of warrants for the three months ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Number of Warrants** | <br>**Weighted-Average**<br>**Exercise Price** | <br>**Remaining**<br>**Contractual Term** | **Aggregate**<br>**Intrinsic**<br>**Value ($ in**<br>**thousands)** |
| Warrants outstanding and exercisable – December 31, 2025 | 140824982 | $0.27 | 2.7 | $— |
| Warrants issued in 2026 |  |  |  |  |
| Warrants exercised 2026 |  |  |  |  |
| Warrants expired in 2026 | (36198) | 0.49 |  |  |
| Warrants outstanding and exercisable – March 31, 2026 | 140788784 | $0.27 | 2.5 | $— |

---

On February 17, 2025, the Company issued a total of 1,042,000 Pre-Funded Warrants to purchase one share of Common Stock per Pre-Funded Warrant, 1,600,000 Series A Warrants to purchase 0.25 share of Common Stock per Series A Warrant, and 1,600,000 Series B Warrants to purchase one share of Common Stock per Series B Warrant in connection with the Public Offering. The Series A Warrants are exchangeable in the ratio of four Series A Warrants for one share of Common Stock.

The Company assessed the Pre-Funded Warrants and Series A Warrants under ASC 480 and ASC 815 and determined that the Pre-Funded and Series A Warrants met the requirements to be classified in stockholders' equity. The Company assessed the Series B Warrants under ASC 480 and ASC 815 and determined that the Series B Warrants will be classified as liabilities as they do not meet the requirements to be considered indexed to the Company's own stock, due to the potential change in the settlement amount of the Series B Warrants upon an alternative cashless exercise election.

The Company utilized a scenario-based option pricing model to calculate the value of the Series B Warrants issued during the year ended December 31, 2025. The fair value of the Series B Warrants of $18.9 million was estimated at the date of issuance using the following inputs and assumptions: the issuance date closing stock price of $3.95, the number of Series B Warrants issued totaling 1,600,000, and a 100% probability of the investors' election for alternative cashless exercise at a ratio of Common Stock per Series B Warrant of 3:1 upon receipt of the Warrant Stockholder Approval. The Warrant Stockholder Approval was obtained on April 10, 2025.

[**Table of Contents**](#TOC)

During the three months ended March 31, 2025, the Company recorded a gain of approximately $10.6 million related to the change in fair value of the warrant liability which is recorded in other income (expense) on the consolidated statement of operations. The fair value of the remaining outstanding Series B Warrants of approximately $1,000 was estimated at December 31, 2025 utilizing a scenario-based option pricing model using the following inputs and assumptions: the valuation date stock price of $0.02, the number of Series B Warrants outstanding as of the valuation date totaling 36,198, and a 100% probability of the investors' election for alternative cashless exercise at a ratio of Common Stock per Series B Warrant of 3:1 after receipt of the Warrant Stockholder Approval. As of March 31, 2026, there were no Series B Warrants outstanding as they had all expired.

#### 8)&nbsp;&nbsp;&nbsp;&nbsp;Dilutive convertible securities
The following table summarizes the potentially dilutive securities convertible into shares of Common Stock that were excluded from the calculation of diluted net income (loss) per share because their inclusion would have been antidilutive:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** |
|  | **March 31,**  | **March 31,**  |
|  | **2026** | **2025** |
| Stock options | 14624 | 14624 |
| RSAs and RSUs | 3981500 | 88000 |
| Series A Convertible Preferred stock |  |  |
| Warrants | 140788784 | 5936405 |
| **Total** | 144784908 | 6039029 |

---

#### 9)&nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies
*(a)&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings*

From time to time, the Company is involved in various legal matters arising in the normal course of business. The Company does not expect the outcome of such proceedings, either individually or in the aggregate, to have a material effect on the Company's financial position, cash flows or results of operations.

#### 10)&nbsp;&nbsp;&nbsp;&nbsp;Segment Information
During 2025, the Company has reorganized its business operations resulting in a change in the number of reportable segments. As a result of the Vivus Termination Agreement (as defined herein) entered into by the Company in March 2025, the Company is no longer engaged in the commercialization, development or sales of Stendra®. Additionally, Metuchen, Timm Medical and PTV have been assigned to a third-party in connection with the ABC (as defined herein), and accordingly, the Company is no longer engaged in the marketing or selling of VEDs. As a result, two segments, Prescription Medications and Medical Devices have been reclassified as discontinued operations. Accordingly, subsequent to the ABC the Company operations comprise a single operating segment at the consolidated level. The Company's chief operating decision maker (the "CODM") reviews and evaluates consolidated net income as presented in the accompanying consolidated statements of operations for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

**11)&nbsp;&nbsp;&nbsp;&nbsp;Fair Value Measurements**

The Company maintains cash in checking and money market accounts with financial institutions. The Company considers all highly liquid investments purchased with an original maturity of three months or less from the time they are acquired to be cash equivalents. The Company had approximately $4.3 million of cash equivalents as of March 31, 2026, and approximately $4.7 million as of December 31, 2025.

Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the year ended December 31, 2025. The carrying amounts of cash equivalents, other current assets, other assets, accounts payable, and accrued expenses approximated their fair values as of March 31, 2026, due to their short-term nature.

[**Table of Contents**](#TOC)

#### ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
*Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of Petros' financial statements with a narrative from the perspective of management on the Company's financial condition, results of operations, liquidity and certain other factors that may affect future results. In certain instances, parenthetical references are made to relevant sections of the Notes to Condensed Consolidated Financial Statements to direct the reader to a further detailed discussion. This section should be read in conjunction with the Consolidated Financial Statements and Supplementary Data included in this Quarterly Report on Form 10-Q. This MD&A contains forward-looking statements reflecting Petros' current expectations, whose actual outcomes involve risks and uncertainties. Actual results and the timing of events may differ materially from those stated in or implied by these forward-looking statements due to a number of factors, including those discussed in the sections entitled "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" contained in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025.*

#### Overview
Petros was incorporated in Delaware on May 14, 2020, for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (as amended, the "Merger Agreement"), by and between Petros, Neurotrope, Inc., a Nevada corporation ("Neurotrope"), Metuchen Pharmaceuticals LLC, a Delaware limited liability company ("Metuchen"), and certain subsidiaries of Petros and Neurotrope. Prior to June 2025, Petros consisted of wholly owned subsidiaries: Metuchen, Neurotrope, Timm Medical Technologies, Inc. ("Timm Medical"), and Pos-T-Vac, LLC ("PTV" and, collectively with Metuchen and Timm Medical, the "Subsidiaries"). The Company has historically been engaged in the commercialization and development of Stendra®, a U.S. Food and Drug Administration ("FDA") approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction ("ED"), which the Company licensed from Vivus, Inc. ("Vivus"). Petros also historically marketed its own line of ED products in the form of vacuum erection device products ("VEDs") through its previous subsidiaries, Timm Medical and PTV, including VEDs marketed as "Osbon ErecAid" and "PosTVac."

In December 2024, the Company determined to discontinue sales of Stendra® to wholesalers. Beginning in March 2025, the Company is no longer engaged in the commercialization, development or sales of Stendra®. In addition, on June 16, 2025, in accordance with California state law, the Company effected an assignment (the "Assignment") of all of the business, assets, properties, contractual rights, goodwill, going concern value, rights and claims ("Assets") of Metuchen, including Metuchen's wholly-owned subsidiaries, Timm Medical and PTV and each of their respective Assets (collectively, the "ABC Assets"), for the benefit of creditors to a special purpose vehicle that is managed by a third-party fiduciary (the "Assignee") such that, as of June 16, 2025, the Assignee succeeded to all of each Subsidiary's right, title and interest in and to the respective ABC Assets. Upon the completion of the Assignment, the Assignee obtained sole control over the ABC Assets and each Subsidiary no longer operates its business or controls the liquidation or distribution of its assets or the resolution of claims. The Assignment is a judicial insolvency procedure, which was commenced by each Subsidiary entering a contractual assignment for the benefit of creditors on June 16, 2025, that effectuates the assignment, grant, conveyance, transfer, and setting over to the Assignee, in trust, of all of the ABC Assets. Accordingly, the Company is no longer engaged in the marketing or selling of VEDs following the completion of the Assignment. Today, the Company is working towards the goal of becoming a leading innovator in the emerging self-care market driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter ("OTC") and nonprescription drug products with additional condition for nonprescription use ("ACNU Products") treatment options.

Petros is pursuing the development of a proprietary integrated technology solutions platform (the "platform") containing two components (i) SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and (ii) a potential Software as a Medical Device ("SaMD") component, which must comply with FDA governance and approval and is expected to be a consumer interface that guides the consumer in navigating appropriate self-selection or deselection, through the acquisition process of the OTC product. The Company has been working towards the development of the platform, which is currently in early development stages and is being designed to serve as a retail or online interface, with clinically established algorithmic logic qualifying the intended consumer-patient for purchase and use of an ACNU Product, while reducing subjectivity to the least possible degree and maximizing objective qualifiers to the greatest possible degree.

[**Table of Contents**](#TOC)

We believe our platform will be anchored in recent FDA adopted rules, such as the FDA's Nonprescription Drug Product with an Additional Condition for Nonprescription Use rule ("ACNU Rule"), intended to increase options to develop and market nonprescription drug products; Trusted Exchange Framework and Common Agreement ("TEFCA"), a nationwide framework for health information sharing; and Qualified Health Information Networks, which are sponsored by the FDA and the Department of Health and Human Services.

**Discontinued Operations**

In connection with the Assignment, the results of the Subsidiaries are presented as discontinued operations in the accompanying unaudited condensed consolidated financial statements. Management's discussion and analysis of the Company's financial condition and results of operations that follows reflects the continuing operations of the Company. The Company's liquidity is likely to be significantly affected by the discontinued operations, as Metuchen accounted for a significant portion of the Company's revenue. Without this revenue stream, the Company may face challenges generating sufficient cash flow to fund operations, unless it secures alternative income sources or financing.

**Reverse Stock Split**

On April 29, 2025, the Company filed a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to effect a 1-for-25 reverse stock split of the shares of the Company's Common Stock, either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (New York time) on April 30, 2025 (the "Reverse Stock Split") and began trading on a Reverse Stock Split-adjusted basis on Nasdaq on May 1, 2025. All share amounts have been retroactively adjusted for the Reverse Stock Split.

**Critical Accounting Estimates**

The preparation of the unaudited condensed consolidated financial statements requires us to make assumptions, estimates and judgments that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Certain of our more critical accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. On an ongoing basis, we evaluate our judgments, including but not limited to those related to income taxes, litigation, and contingencies. We use historical experience and other assumptions as the basis for our judgments and making these estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in those estimates will be reflected in our condensed consolidated financial statements as they occur.

Our critical accounting estimates have not changed materially from those described in Part II, Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026.

[**Table of Contents**](#TOC)

**Results of Operations**

#### Three Months Ended March 31, 2026, and 2025 (Unaudited)
The following table sets forth a summary of our statements of operations for the three months ended March 31, 2026, and 2025:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,**  | **For the Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| Operating expenses: |  |  |
| &nbsp;&nbsp;Selling, general and administrative | 1027179 | 1458349 |
| Total operating expenses | 1027179 | 1458349 |
| Loss from continuing operations | (1027179) | (1458349) |
| Other income (expenses): |  |  |
| &nbsp;&nbsp;Warrant issuance costs |  | (10420982) |
| &nbsp;&nbsp;Change in fair value of warrant liability |  | 10632000 |
| &nbsp;&nbsp;Interest income | 40143 | 47790 |
| Total other income (expenses) | 40143 | 258808 |
| Loss before income taxes | (987036) | (1199541) |
| Provision for income taxes |  |  |
| Loss from continuing operations, net of tax | (987036) | (1199541) |
| Loss from discontinued operations |  | (1060481) |
| Net loss | $(987036) | $(2260022) |

---

***Operating Expenses***

Selling, general and administrative expenses for the three months ended March 31, 2026, and March 31, 2025, were $1,027,179 and $1,458,349, respectively. Selling, general and administrative expenses include administrative and corporate expenses.

Selling, general and administrative expenses decreased by $431,170 or 30% during the three months ended March 31, 2026, compared to the three months ended March 31, 2025. Decreased selling, general and administrative expenses were primarily driven by decreased professional service fees of $408,646 and decreased other operating expenses of $82,646 partially offset by increased payroll and benefits expenses of $19,841 and increased stock-based compensation expense of $40,281.

***Warrant Issuance Costs***

Warrant issuance costs for the three months ended March 31, 2026, and March 31, 2025, were $0 and $10,420,982, respectively. The warrant issuance costs of $10.4 million were associated with the February 2025 Public Offering (as defined herein).

***Change in fair value of warrant liability***

For the three months ended March 31, 2026, and March 31, 2025, the Company recorded a gain of approximately $0.0 million and $10.6 million, respectively, for the change in fair value of the warrant liability. The gain in 2025 was related to the decrease in fair value of the Series Warrants issued in the Public Offering.

***Interest Income***

Interest income for the three months ended March 31, 2026, and March 31, 2025, was $40,143 and $47,790, respectively. Petros invested its cash in money market securities during 2025 and 2024.

[**Table of Contents**](#TOC)

***Loss on Discontinued Operations***

For the three months ended March 31, 2026, and March 31, 2025, the Company recorded losses of $0.0 million and $1.1 million, respectively, from discontinued operations.

**Liquidity and Capital Resources**

Historically, the Company has raised capital through private placements of convertible preferred stock and warrants and through public offerings of its securities. The Company's future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily limited to, the success and costs of commercialization of the Company's platform. We will require additional financing to further develop and market future products, fund operations, and otherwise implement our business strategy at amounts relatively consistent with the expenditure levels disclosed herein. We are exploring additional ways to raise capital, but we cannot assure you that we will be able to raise capital. Our failure to raise capital as and when needed would have a material adverse impact on our financial condition, our ability to meet our obligations, and our ability to pursue our business strategies. We expect to seek additional funds through a variety of sources, which may include additional public or private equity or debt financings, collaborative, or other arrangements with corporate sources, or through other sources of financing.

The Company is focused on expanding our service offering through internal development, collaborations, and through strategic acquisitions. We are continually evaluating potential asset acquisitions and business combinations. To finance such acquisitions, we might raise additional equity capital, incur additional debt, or both. However, adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or debt, the terms of these securities may restrict our ability to operate. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether cease our research and development programs or future commercialization efforts of our platform.

***Nasdaq Delisting and OTC Trading***

On May 20, 2025, the Company received a letter from the Nasdaq Hearings Panel (the "Panel") indicating that the Panel determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") as a result of (i) the Company's failure to maintain compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), (ii) the Company's failure to meet the minimum bid price of $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2), (iii) the Company's low bid price pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii), and (iv) Nasdaq's public interest concerns regarding the Company's public offering of securities that closed on February 19, 2025, pursuant to Nasdaq Listing Rule 5810(d). Pursuant to the letter, the Panel determined to deny the Company's request to continue its listing on Nasdaq and the Company's Common Stock was suspended at the open of trading on May 22, 2025. On November 7, 2025, Nasdaq announced the delisting of the Company's Common Stock and filed a Form 25 with the SEC to complete the delisting in accordance with Rule 12d2-2 promulgated under the Exchange Act. The delisting became effective ten days after the Form 25 was filed.

As a result of the delisting, the Company's Common Stock now trades on the OTCID® Basic Market (the "OTCID") under the symbol "PTPI." Trading on the OTCID market may limit the liquidity of the Company's Common Stock, making it more difficult for investors to buy or sell shares at desired prices or in desired quantities. In addition, OTCID markets are generally less regulated and more volatile than national securities exchanges. The lack of analyst coverage and lower visibility may also reduce investor interest and negatively affect the Company's stock price. Furthermore, the delisting may hinder the Company's ability to raise capital, attract institutional investors, or retain key personnel.

*Going Concern*

The Company has experienced net losses and negative cash flows from operations since our inception. As of March 31, 2026, the Company had cash and cash equivalents of approximately $4.4 million, working capital of $1.8 million from continuing operations, an accumulated deficit of approximately $112.3 million and used cash in operations during the three months ended March 31, 2026, of approximately $0.8 million.

The Company does not currently have sufficient available liquidity to fund its operations for at least the next 12 months. These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these

[**Table of Contents**](#TOC)

condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that might result from these uncertainties. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

In response to these conditions and events, the Company is evaluating various financing strategies to obtain sufficient additional liquidity to meet its operating, debt service and capital requirements for the next twelve months following the date of our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The potential sources of financing that the Company is evaluating include one or any combination of secured or unsecured debt, convertible debt and equity in both public and private offerings. The Company also plans to finance near-term operations by exploring additional ways to raise capital and increasing cash flows from operations. There is no assurance the Company will manage to raise additional capital or otherwise increase cash flows, if required or that the Company will have sufficient cash to develop its platform.

***February 2025 Equity Financing***

On February 17, 2025, the Company entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional and accredited investors (collectively, the "Investors") for the issuance and sale, in a best efforts public offering (the "Public Offering"), of (i) 558,000 units (the "Units"), each Unit consisting of one share (the "Shares") of the Company's Common Stock, one Series A Warrant (the "Series A Warrants") to purchase 0.25 share of Common Stock (the "Series A Warrant Shares") and one Series B Warrant (the "Series B Warrants," and together with the Series A Warrants, the "Series Warrants") to purchase one shares of Common Stock (the "Series B Warrant Shares" and, together with the Series A Warrant Shares, the "Series Warrant Shares") and (ii) 1,042,000 pre-funded units (the "Pre-Funded Units"), each Pre-Funded Unit consisting of one pre-funded warrant (the "Pre-Funded Warrants") to purchase one share of Common Stock (the "Pre-Funded Warrant Shares"), one Series A Warrant and one Series B Warrant. The public offering price was $6.00 per Unit and $5.9975 per Pre-Funded Unit. The Offering closed on February 19, 2025. The initial exercise price of each of the Series A Warrants and the Series B Warrants was $12.00 per share of Common Stock, which was subsequently adjusted as set forth herein. The aggregate gross proceeds from the Offering were approximately $9.6 million before deducting estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The Company considers the change in exercise price due to the anti-dilution trigger related to the Series A Preferred Warrants to be of an equity nature, as the issuance allowed the warrant holders to exercise warrants in exchange for Common Stock, which represents an equity for equity exchange. Therefore, the change in the fair value of the Warrants before and after the effect of the anti-dilution triggering event will be treated as a deemed dividend in the amount of approximately $8.4 million during the three months ended March 31, 2025. The Company valued the initial deemed dividend as the difference between: (a) the modified fair value of the Warrants in the amount of approximately $9.1 million and (b) the fair value of the original award prior to the modification of approximately $0.7 million. The fair value of the Series A Preferred Warrants before the effect of the anti-dilution triggering event was estimated utilizing the Black Scholes model using the following key inputs and assumptions: the number of shares issuable upon exercise of the Series A Preferred Warrants totaling 288,000; the exercise price of $56.25; dividend yield of 0%; remaining term of 3.40 years; equity volatility of 165.0%; and a risk-free interest rate of 4.3%. The fair value of the Warrants after the effect of the anti-dilution triggering event was estimated utilizing the Black Scholes model and the following key inputs and assumptions: the number of shares issuable upon exercise of the Series A Preferred Warrants totaling 2,700,000; the exercise price of $6.00; dividend yield of 0%; remaining term of 3.40 years; equity volatility of 165.0%; and a risk-free interest rate of 4.3%.

In connection with the Public Offering, (i) the conversion price of the Series A Preferred Stock was adjusted to $6.00 per share pursuant to the full ratchet anti-dilution provisions contained in the Certificate of Designations and, (ii) the exercise price of the Warrants was adjusted to $6.00 per share and the number of shares of Common Stock issuable upon exercise of the Warrants was adjusted proportionally to 2,700,000 shares pursuant to the full ratchet anti-dilution provisions contained in the Warrants (the "Public Offering Warrant Adjustment"). In connection with the Company's 1-for-25 Reverse Stock Split and pursuant to the share combination event adjustment provisions in the Series A Certificate of Designations, the conversion price of the Series A Preferred Stock was further adjusted to $0.1269.

[**Table of Contents**](#TOC)

Dawson James Securities, Inc. ("Dawson") acted as the Company's exclusive placement agent in connection with the Public Offering, pursuant to that certain engagement letter, dated as of January 24, 2025, between the Company and Dawson (the "Engagement Letter"). Pursuant to the Engagement Letter, the Company agreed to pay Dawson a cash fee equal to 8.0% of the aggregate gross proceeds of the Public Offering and reimbursed certain expenses and legal fees.

The aggregate gross proceeds from the Public Offering were approximately $9.6 million before deducting estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

The Company assessed the Pre-Funded Warrants and Series A Warrants under ASC 480 and ASC 815 and determined that the Pre-Funded and Series A Warrants met the requirements to be classified in stockholders' equity. However, as discussed in the following paragraph, as the fair value of the Series B Warrants exceeded the proceeds received from the Public Offering, and thus the Pre-Funded Warrants and Series A Warrants were recorded at their residual fair value of $0 upon issuance.

Transaction costs incurred attributable to the Series B Warrants of approximately $10.4 million were expensed immediately upon issuance, of which approximately $1.1 million represents cash broker and legal fees, and approximately $9.3 million represents the excess of the issuance date fair value of the Series B Warrants over cash proceeds.

***July 2023 Private Placement***

On July 13, 2023, we entered into the Purchase Agreement with certain accredited investors (the "Investors"), pursuant to which we agreed to sell in a private placement to the Investors (i) an aggregate of 15,000 shares of our newly-designated Series A Preferred Stock initially convertible into up to 266,667 shares of our Common Stock (ii) Warrants to acquire up to an aggregate of 266,667 shares of Common Stock.

*Series A Preferred Stock*

The terms of the Series A Preferred Stock are as set forth in the form of Certificate of Designations. The Series A Preferred Stock is convertible into shares of Common Stock (the "Conversion Shares") at the election of the holder at any time at an initial conversion price of $56.25 (the "Conversion Price"). The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions).

Pursuant to the Certificate of Designations and prior to the November 2024 Certificate of Amendment (as defined below) and the January 2025 Certificate of Amendment (as defined below), we were initially required to redeem the Series A Preferred Stock in 13 equal monthly installments, which commenced on November 1, 2023.

On November 13, 2024, the Company entered into an Amendment Agreement with the Required Holders (as defined in the Certificate of Designations), pursuant to which, the Required Holders agreed to (i) amend the Certificate of Designations, by filing a Certificate of Amendment with the Secretary of State of the State of Delaware (the "November 2024 Certificate of Amendment"), (ii) defer any payment amounts that have accrued and that are unpaid as of November 13, 2024, pursuant to the Certificate of Designations, to January 15, 2025, and (iii) waive any breach or violation of the Purchase Agreement, the Certificate of Designations, or the Warrants resulting from the Company's failure to pay such outstanding amounts (the "November 2024 Certificate of Amendment"). The November 2024 Certificate of Amendment amends the Certificate of Designations to, (i) extend the maturity date to January 15, 2025, (ii) modify the schedule of Installment Dates (as defined in the Certificate of Designations), and (iii) adds an additional restrictive covenant to the Certificate of Designations requiring the Company from November 13, 2024 until January 15, 2025, to maintain unencumbered, unrestricted cash and cash equivalents on hand in amount equal to at least $1,500,000. The November 2024 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of November 13, 2024.

[**Table of Contents**](#TOC)

On January 23, 2025, the Company entered into an Amendment Agreement with the Required Holders (as defined in the Certificate of Designations), pursuant to which, the Required Holders agreed to (i) amend the Certificate of Designations of the Company's Series A Preferred Stock by filing a Certificate of Amendment to the Certificate of Designations (the "January 2025 Certificate of Amendment") with the Secretary of State of the State of Delaware, (ii) defer any payment amounts that have accrued and that are unpaid as of January 23, 2025, pursuant to the Certificate of Designations, to February 15, 2025, and (iii) waive any breach or violation of the Purchase Agreement, the Certificate of Designations, or the Warrants resulting from the Company's failure to pay such outstanding amounts. The January 2025 Certificate of Amendment amends the Certificate of Designations to, (i) extend the maturity date to February 15, 2025, (ii) modify the schedule of Installment Dates (as defined in the Certificate of Designations), (iii) amends the restrictive covenant to the Certificate of Designations requiring the Company from January 15, 2025 until February 15, 2025, to maintain unencumbered, unrestricted cash and cash equivalents on hand in amount equal to at least $500,000, and (iv) amends the restrictive covenant relating to the change in nature of the Company's business, such that such covenant does not apply to the Company's change in sales strategy related to the Company's Stendra® avanafil and product development strategy as it relates to the development and commercialization of a proprietary platform focused on prescription medication to over-the-counter switch solutions. The January 2025 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of January 24, 2025.

On March 30, 2025, the Company entered into an Amendment Agreement (the "March 2025 Amendment Agreement") with the Required Holders (as defined in the Certificate of Designations), pursuant to which, the Required Holders agreed to (i) amend the Certificate of Designations of the Company's Series A Preferred Stock by filing a Certificate of Amendment to the Certificate of Designations (the "March 2025 Certificate of Amendment") with the Secretary of State of the State of Delaware, (ii) defer any payment amounts that have accrued and that are unpaid as of the date of the March 2025 Amendment Agreement, pursuant to the Certificate of Designations, to July 15, 2025, and (iii) waive any breach or violation of the Purchase Agreement, the Certificate of Designations, or the Warrants resulting from the Company's failure to pay such outstanding amounts. The March 2025 Certificate of Amendment amends the Certificate of Designations to, (i) extend the maturity date to July 15, 2025, and (ii) modify the schedule of Installment Dates (as defined in the Certificate of Designations). The March 2025 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of March 31, 2025.

The amortization payments due upon redemptions are payable, at our election, in cash at 107% of the Installment Redemption Amount (as defined in the Certificate of Designations), or subject to certain limitations, in shares of Common Stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) 80% of the average of the three lowest closing prices of the Common Stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) $9.90 or such lower amount as permitted, from time to time, by the Nasdaq Stock Market, subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events.

The holders of the Series A Preferred Stock are entitled to dividends of 8% per annum, compounded monthly, which are payable, at our option, in cash or shares of Common Stock, or in a combination thereof, in accordance with the terms of the Certificate of Designations. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Series A Preferred Stock will accrue dividends at the rate of 15% per annum. In connection with a Triggering Event, each holder of Series A Preferred Stock will be able to require us to redeem in cash any or all of the holder's Series A Preferred Stock at a premium set forth in the Certificate of Designations. Upon conversion or redemption, the holders of the Series A Preferred Stock are also entitled to receive a dividend make-whole payment.

The event of default under the Settlement Agreement and the Security Agreement with Vivus existing and continuing by virtue of Metuchen's failure to pay the Installment (as defined in the Promissory Note) that was due October 1, 2024, constitutes a Triggering Event pursuant to the terms of the Certificate of Designations. As a result, the dividend rate of the Series A Preferred Stock was automatically increased to 15% per annum beginning on October 1, 2024.

On October 11, 2024, the Company entered into an Amendment Agreement with the Required Holders (as defined in the Certificate of Designations) pursuant to which, the Required Holders agreed to amend the Certificate of Designations of the Company's Series A Preferred Stock, by filing a Certificate of Amendment with the Secretary of State of the State of Delaware ("October 2024 Certificate of Amendment"). The October 2024 Certificate of Amendment amends the Certificate of Designations to, among other things, provide that, except as required by applicable law, the holders of the Series A Preferred Stock will be entitled to vote with holders of the Common Stock on an as converted basis, with the number of votes to which each holder of Series A Preferred Stock is entitled to be determined by dividing the Stated Value (as defined in the Certificate of Designations) by a conversion price equal to $56.25 per share, which was the "Minimum Price" (as defined in Nasdaq Listing Rule 5635(d)) applicable immediately before the execution and delivery of the purchase agreement executed in connection with the issuance of the Series A Preferred Stockequal, subject to certain beneficial

[**Table of Contents**](#TOC)

ownership limitations and adjustments for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions, as set forth in the Certificate of Designations. The October 2024 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of October 11, 2024.

As of March 31, 2026, the conversion price of the Series A Preferred Stock was $0.1269 per share.

The Company is subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends (other than dividends pursuant to the Certificate of Designations), distributions or redemptions, and the transfer of assets, among other matters.

There is no established public trading market for the Series A Preferred Stock and we do not intend to list the Series A Preferred Stock on any national securities exchange or nationally recognized trading system.

*Warrants*

The Warrants became exercisable for shares of Common Stock (the "Warrant Shares") immediately upon issuance, at an initial exercise price of $56.25 per share (the "Exercise Price") and expire five years from the date of issuance. The Exercise Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a "full ratchet" basis, in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Exercise Price (subject to certain exceptions). Upon any such price-based adjustment, the number of Warrant Shares issuable upon exercise of the Warrants will be increased proportionately. There is no established public trading market for the Warrants and we do not intend to list the Warrants on any national securities exchange or nationally recognized trading system.

On March 21, 2024, we entered into the Waiver and Amendment with the Investors in the Private Placement, effective as of December 31, 2023. The Waiver and Amendment, among other things, amended certain terms of the Warrants relating to the rights of the holders of the Warrants to provide that, in the event of a Fundamental Transaction (as defined in the Warrants) that is not within our control, including not approved by our Board of Directors, the holder of a Warrant shall only be entitled to receive from the Company or any successor entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of such Warrant, that is being offered and paid to the holders of our Common Stock in connection with the Fundamental Transaction.

As of March 31, 2026, the exercise price of the Warrants was $0.1269 per share.

*Registration Rights*

In connection with the Private Placement, we entered into a Registration Rights Agreement with the Investors (the "Registration Rights Agreement"), pursuant to which we agreed to file a resale registration statement (the "Registration Statement") with the SEC to register for resale 200% of the Conversion Shares and the Warrant Shares promptly following the Closing Date (as defined in the Purchase Agreement), but in no event later than 30 calendar days after the effective date of the Registration Rights Agreement, and to have such Registration Statement declared effective by the Effectiveness Date (as defined in the Registration Rights Agreement). We filed a registration statement on Form S-3 covering such securities, which registration statement, as amended, was declared effective on September 18, 2023. Under the Registration Rights Agreement, we are obligated to pay certain liquidated damages to the investors if we fail to maintain the effectiveness of the Registration Statement.

We will require additional financing to further develop and market our products, fund operations, and otherwise implement our business strategy at amounts relatively consistent with the expenditure levels disclosed above. We are exploring additional ways to raise capital, but we cannot assure you that we will be able to raise capital. Our failure to raise capital as and when needed would have a material adverse impact on our financial condition, our ability to meet our obligations, and our ability to pursue our business strategies. We expect to seek additional funds through a variety of sources, which may include additional public or private equity or debt financings, collaborative, or other arrangements with corporate sources, or through other sources of financing.

We are focused on expanding our service offering through internal development, collaborations, and through strategic acquisitions. We are continually evaluating potential asset acquisitions and business combinations. To finance such acquisitions, we might raise additional equity capital, incur additional debt, or both.

[**Table of Contents**](#TOC)

#### Cash Flows
The following table summarizes the Company's cash flows for the three months ended March 31, 2026, and 2025:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,**  | **For the Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| Net cash used in operating activities – continuing operations | $(784272) | $(1494593) |
| Net cash provided by (used in) financing activities – continuing operations |  | 8707002 |
| Net increase (decrease) in cash and cash equivalents – continuing operations | $(784272) | $7212409 |

---

*Cash Flows from Operating Activities*

Net cash used in operating activities for the three months ended March 31, 2026, was $784,272, which primarily reflected the Company's net loss of $1,027,179, which was inclusive of noncash adjustments to reconcile net loss to net cash used in operating activities of $120,319 consisting of the employee stock-based compensation expense, and changes in operating assets and liabilities of $82,445 largely driven by accounts payable and accrued expenses related to professional fees and employee bonuses.

Net cash used in operating activities for the three months ended March 31, 2025, was $1,494,593, which primarily reflected the Company's net loss of $1,199,541, in addition to noncash adjustments to reconcile net loss to net cash used in operating activities of $130,980 consisting of the change in the fair value of the warrant liability, noncash warrant expense, and stock-based compensation, and changes in operating assets and liabilities of $164,072 largely driven by accrued expenses related to professional fees and employee bonuses and equity issuance fees.

*Cash Flows from Financing Activities*

Net cash provided by financing activities was $0 for the three months ended March 31, 2026.

Net cash provided by financing activities was $8,707,002 for the three months ended March 31, 2025, consisting of proceeds from the February 2025 Equity Financing.

**Off-Balance Sheet Commitments and Arrangements**

The Company has not entered into any off-balance sheet financial guarantees or other off-balance sheet commitments to guarantee the payment obligations of any third parties. The Company has not entered into any derivative contracts that are indexed to the Company's shares and classified as stockholder's equity or that are not reflected in the Company's financial statements included in this Quarterly Report on Form 10-Q. Furthermore, the Company does not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. The Company does not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or product development services with us.

**Contingencies**

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company's management, in consultation with its legal counsel as appropriate, assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company, in consultation with legal counsel, evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates a potentially material loss contingency is not probable, but is reasonably possible, or is probable, but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

[**Table of Contents**](#TOC)

#### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

#### ITEM 4. CONTROLS AND PROCEDURES.

#### Evaluation of Disclosure Controls and Procedures
We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act")) as of the period covered by this report. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this Quarterly Report on Form 10-Q, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

A material weakness is a control deficiency (within the meaning of Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 5) or combination of control deficiencies that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. As disclosed in Part II Item 9A Controls and Procedures in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, we identified a material weaknesses in internal control related to (1) Petros has an insufficient level of monitoring and oversight controls and does not enforce the implementation of key controls reflected on its internal control process matrices; (2) the sizes of Petros' accounting and IT departments make it impracticable to achieve an appropriate segregation of duties; and (3) Petros does not have appropriate IT access related controls.

Management plans to expand the scope of its remediation of its internal controls over financial reporting at the consolidated level and has developed a plan to address the remediation of the foregoing deficiencies. Petros' remediation efforts are ongoing and it will continue its initiatives to implement and document policies, procedures, and internal controls. The remediation efforts include the implementation of additional controls to ensure all risks have been addressed. Management is further emphasizing compliance with existing internal controls. The Company has continued to utilize an external consultant to assist in the remediation of the deficiencies.

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Management believes that the financial statements included in this Quarterly Report on Form 10-Q fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

#### Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting other than as noted above.

[**Table of Contents**](#TOC)

#### PART II—OTHER INFORMATION

#### ITEM 1. LEGAL PROCEEDINGS.
From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of business.

The information set forth in Note 9 Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q is incorporated by reference herein.

#### ITEM 1A. RISK FACTORS.
The following description of risk factors includes any material changes to, and supersedes the description of, risk factors associated with our business, financial condition and results of operations previously disclosed in "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on April 15, 2026. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in our annual report, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results, and stock price.

The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding other statements in this Quarterly Report on Form 10-Q. The following information should be read in conjunction with the condensed consolidated financial statements and related notes in Part I, Item 1, "Financial Statements" and Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of this Quarterly Report on Form 10-Q.

***The Company's financial statements have been prepared on a going concern basis and do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management has substantial doubt about the Company's ability to continue as a going concern.***

The Company's unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the three months ended March 31, 2026, the Company's cash used in operations was $784,272, leaving a cash balance of $4,352,450 as of March 31, 2026. Because the Company does not have sufficient resources to fund its operations for the next twelve months from the date of this filing, management has substantial doubt about the Company's ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability. There are no assurances that the Company would be able to raise additional capital on terms favorable to it. If the Company is unsuccessful in commercializing its products and raising capital, it will need to reduce activities, curtail or cease operations.

#### ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
There were no unregistered sales of the Company's equity securities during the three months ended March 31, 2026, other than those previously reported in a Current Report on Form 8-K.

#### ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.

#### ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.

#### ITEM 5. OTHER INFORMATION.
None.

[**Table of Contents**](#TOC)

**ITEM 6. EXHIBITS.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 31.1\* | [Rule 13a-14(a)/15d-14(a) Certification – Principal Executive Officer.](tmb-20260331xex31d1.htm) |
| 31.2\* | [Rule 13a-14(a)/15d-14(a) Certification – Principal Financial Officer.](tmb-20260331xex31d2.htm) |
| 32.1\*\* | [Section 1350 Certification – Principal Executive Officer.](tmb-20260331xex32d1.htm)  |
| 32.2\*\* | [Section 1350 Certification – Principal Financial Officer.](tmb-20260331xex32d2.htm) |
| 101 | The following materials from Petros Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Changes in Stockholders' Equity/Members' Capital; (iv) Consolidated Statements of Cash Flows; and (v) Notes to the Condensed Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101. |

---

\* Filed herewith.

\*\* Furnished herewith.

[**Table of Contents**](#TOC)

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Petros Pharmaceuticals, Inc. | Petros Pharmaceuticals, Inc. |
| Date: May 13, 2026 | By: | /s/ Fady Boctor |
|  |  | Fady Boctor |
|  |  | Chief Commercial Officer and Principal Executive Officer |
| Date: May 13, 2026 | By: | /s/ Mitchell Arnold |
|  |  | Mitchell Arnold |
|  |  | Vice President of Finance and Principal Financial Officer |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO SARBANES–OXLEY ACT OF 2002**

I, Fady Boctor, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of Petros Pharmaceuticals, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | /s/ Fady Boctor |
|  |  | Fady Boctor |
|  |  | Chief Commercial Officer and Principal Executive Officer |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO SARBANES–OXLEY ACT OF 2002**

I, Mitchell Arnold, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q of Petros Pharmaceuticals, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 13, 2026 | By: | /s/ Mitchell Arnold |
|  |  | Mitchell Arnold |
|  |  | Vice President of Finance and Principal Financial Officer |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO SECTION 906**

**OF THE SARBANES–OXLEY ACT OF 2002**

In connection with the Quarterly Report of Petros Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
|  | Petros Pharmaceuticals, Inc. | Petros Pharmaceuticals, Inc. |
| Date: May 13, 2026 | By: | /s/ Fady Boctor |
|  |  | Fady Boctor |
|  |  | Chief Commercial Officer and Principal Executive Officer |

---

------

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO SECTION 906**

**OF THE SARBANES–OXLEY ACT OF 2002**

In connection with the Quarterly Report of Petros Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
|  | Petros Pharmaceuticals, Inc. | Petros Pharmaceuticals, Inc. |
| Date: May 13, 2026 | By: | /s/ Mitchell Arnold |
|  |  | Mitchell Arnold |
|  |  | Vice President of Finance and Principal Financial Officer |

---

------